Thank you, and good morning, everyone. Welcome to our second quarter conference call.

With me here today are Ric Phillips, our Chief Executive Officer, and Jana Croom, Chief Financial Officer. We issued a press release yesterday afternoon with our results for the second quarter of fiscal 2026 ended December 31st, 2025.

To accompany today's call, a presentation has been posted to the Investor Relations page on our company website. Before we get started, I'd like to remind you that we will be making forward-looking statements that involve risk and uncertainty, and are subject to our safe harbor provisions as stated in our press release and SEC filings, and that actual results can differ materially from the forward-looking statements.

Our commentary today will be focused on adjusted non-GAAP results. Reconciliations of GAAP to non-GAAP amounts are available in our press release.

This morning, Rick will start the call with a few opening comments, Jana will review the financial results for the quarter and guidance for fiscal 2026, and Rick will complete our prepared remarks before taking your questions. I'll now turn the call over to Rick.

Thank you, Andy, and good morning, everyone. I'm pleased with the results for the second quarter and our updated guidance for fiscal 2026.

Sales in Q2 were in line with expectations, highlighted by another quarter of strong double-digit year-over-year growth in the medical vertical. Margins improved compared to the same period last year, and cash from operations was positive for the eighth consecutive quarter.

Our focus as a medical CMO continues to gain momentum as we leverage our unique capabilities in the industry. We expect top-line growth in medical to outpace our other two verticals as we balance our portfolio across the markets we serve.

Our recent announcement to rebrand as Kimball Solutions and the grand opening of the new medical manufacturing facility in Indianapolis reflects this strategy and our expanded offering of capabilities and services. Turning to the second quarter, net sales for the company were $341 million, a 5% decline compared to Q2 last year.

From an end-market perspective, the strong results in medical were offset by declines in North American automotive and industrial and continued softness in China. Starting with medical, sales in the second quarter were $96 million, up 15% compared to the same period last year, and 28% of total company sales.

This represents our fourth consecutive quarter of year-over-year revenue growth in this vertical. Approximately half of our medical business is in North America.

The other half is roughly split between Asia and Europe. The increase in Q2 was driven by growth in Poland and Thailand.

North America was flattish in the quarter. We continue to view the medical vertical as a compelling opportunity to diversify our top line and leverage our core strengths as a trusted partner in a complex and highly regulated industry.

Megatrends such as an aging population, increasing access and affordability to healthcare, and smaller medical devices requiring higher levels of precision and accuracy are expected to fuel future growth. Our strategy is to align with new and existing blue-chip customers in need of manufacturing capacity for products with long life cycles and high degrees of visibility.

A great example of this strategy coming to life is our new facility in Indianapolis. Tomorrow, we will be celebrating the grand opening with a ribbon-cutting ceremony and plant tour, showcasing our state-of-the-art facility that adds capacity to our U.S.

footprint for manufacturing medical products, single-use surgical instruments, and drug delivery devices such as auto-injectors. Indy, however, is not the only example.

Thailand, Poland, Mexico, and Jasper also serve the medical market with HLAs and finished medical products. To complement our organic growth, we're actively pursuing disciplined tuck-in acquisitions that could bring new customers, increase exposure to faster-growing end markets, expand our geographic reach, and add manufacturing capabilities, including opportunities for vertical integration.

Together, these strategies strengthen our global platform and position the company for a sustainable return to profitable growth. Next is automotive, with sales of $162 million, down 13% compared to the second quarter of last year, and 48% of the total company.

The decline in Q2 was driven by lower sales in North America, the result of the electronic braking program transfer out of Reynosa in mid-fiscal '25, and recent pressure in the U.S. related to tariffs.

The combined impact represented the majority of the decrease in the quarter, although automotive sales were also down in China. This was partially offset by strong growth in both Poland and Romania, with programs in steering and braking, respectively.

Our company has supported the automotive market since the mid-'80s, and it has become a very good business for us, generating strong cash flow when production volumes are at or above planned levels. Electronic steering and braking applications continue to be our sweet spot, with advances such as steer-by-wire and brake-by-wire or electronic mechanical braking increasing the electronic content on vehicles.

We are also seeing early stages of growth from the full assembly of an EPP, or electronic power pack, a steering system HLA that integrates the motor and the ECU. In addition, OEMs are starting to design in a second steering system in vehicles, this one in the rear of certain higher-end cars and trucks.

Finally, sales in industrial totaled $83 million, a 5% decrease compared to Q2 last year, and 24% of total company sales. Our industrial business is heavily concentrated in North America, where the majority of the decline occurred, with lower demand for HVAC systems.

This was partially offset by higher sales in Europe, a result of a rebound of the smart meter business for us in that region. I'll now turn the call over to Jana for more detail on Q2 and our updated outlook with raised guidance for fiscal 2026.

Jana?

Thank you, and good morning, everyone. As Rick highlighted, net sales in the second quarter were $341.3 million, a 5% decrease year-over-year.

Foreign exchange had a 2% favorable impact on consolidated sales in the quarter. On a sequential basis, sales were down just over 6% compared to Q1, with the decline primarily occurring in the industrial vertical market driven by reduced sales in the North American climate control submarket.

The gross margin rate in the second quarter was 8.2%, a 160 basis point improvement compared to 6.6% in the same period of fiscal 2025, with the increase resulting from favorable mix, the closure of our Tampa facility, favorable FX rates, and our global restructuring efforts. Adjusted selling and administrative expenses in the second quarter were $12.6 million, a $2.5 million increase year-over-year.

When measured as a percentage of sales, the rate was 3.7% this year compared to 2.9% last year. As we previously indicated, expense will be higher in FY '26 as we make strategic investments in business transformation, IT solutions, and business development for the future.

Adjusted operating income in Q2 was $15.3 million, or 4.5% of net sales, which compares to last year's adjusted results of $13.3 million, or 3.7% of net sales. Our improved guidance for adjusted income reflects the impact of higher sales as well as the S&A investments I just spoke about, and the grand opening of our new CMO facility in Indianapolis, where we will incur higher depreciation and other expenses related to the plant opening.

We have worked hard to balance the needs of the business against the backdrop of declining sales. We will continue our restructuring efforts in FY '26 and beyond as we align our cost structure to end-market demand.

Other income and expense was expense of $3.8 million compared to $4.8 million of expense last year. Once again this quarter, interest expense drove the decrease, down 50% year-over-year.

The effective tax rate in Q2 was 47.9% compared to 1.2% last year, with the higher rate driven by the impact of a provision to tax return adjustment and a valuation allowance adjustment associated with the expected sale of the Tampa facility. For the full year of fiscal '26, we continue to expect an effective tax rate in the high 20s to low 30s.

Adjusted net income in the first quarter was $6.9 million, or 28 cents per diluted share, compared to last year's adjusted results of $7.4 million, or 29 cents per diluted share. Turning now to the balance sheet, cash and cash equivalents at December 31st, 2025, were $77.9 million.

Cash generated by operating activities in the quarter was $6.9 million, our eighth consecutive quarter of positive cash flow. Cash conversion days were 91 days, an eight-day increase compared to last quarter, but a 16-day improvement compared to Q2 of fiscal '25.

We are continuing to focus on improving cash conversion days by actively managing the components, and are pleased by our progress thus far. Inventory ended the quarter at $281.7 million, marginally higher than Q1, but down $24.5 million, or 8%, from a year ago.

Capital expenditures in Q2 were $18.2 million, with much of the spend once again this quarter on leasehold improvements in the new facility in Indianapolis. Borrowings at December 31st, 2025, were $154 million, up $16 million from the first quarter, but down $51 million, or roughly 25%, from a year ago.

Short-term liquidity available, represented as cash and cash equivalents plus the unused portion of our credit facilities, totaled $363 million at the end of the second quarter. We invested $4.3 million in Q2 to repurchase 149,000 shares.

Since October 2015, under our Board-authorized share repurchase program, a total of $109.5 million has been returned to our share owners by purchasing 6.8 million shares of common stock. We have $10.5 million remaining on the repurchase program.

As Rick mentioned, we are raising our guidance for fiscal '26, with net sales expected to be in the range of $1.4 to $1.46 billion, which compares to our previous guidance of $1.35 to $1.45 billion. The improvement is driven by strength in the medical vertical as well as the ramp of automotive programs at both European facilities.

Adjusted operating income now estimated to be 4.2 to 4.5% of net sales versus our prior estimate of 4.0 to 4.25%, with the improvement driven by higher sales balanced against investments in our Indianapolis CMO facility, business development needs, and business transformation and IT solutions to further innovations and enhance our capabilities. The guidance for capital expenditures did not change, with a range of $50 to $60 million for the fiscal year.

I'll now turn the call back over to Rick.

Thanks, Jana. Before we open the lines for questions, I'd like to share a few thoughts in closing.

As Jana detailed, we are pleased to raise the outlook for the fiscal year, driven by strength in the medical vertical. We continue to monitor the outlook for FY '27, particularly in the North America automotive and industrial verticals, as the consumer continues to respond to tariff impacts, changes in U.S.

tax subsidies, and economic concerns. We'll provide more color on our outlook as the year progresses.

2026 is a year of milestones for our company, with our facility in Romania celebrating 10 years of operations, China 20 years, and it's the 65th anniversary for the enterprise. As we previously announced, we are celebrating this anniversary and embracing our future with a new company name: Kimball Solutions.

This rebrand is a strategic move that reflects our evolution beyond traditional electronics manufacturing services, with an expanded portfolio of capabilities that includes design and engineering support, supply chain management, precision plastics for medical applications, and high-level and final product assemblies for the verticals we serve. It also embodies our customer-centric approach to long-lasting partnerships, providing end-to-end solutions from design and prototyping to new product introduction, manufacturing, and aftermarket support.

The rebrand will occur in a phased rollout at locations across the global footprint beginning in July of 2026, and will be completed when the company officially changes its name a year later, pending share owners' approval. This change, along with the recent investments in Indianapolis, demonstrates our commitment to innovation and the vision to deliver comprehensive solutions worldwide.

While the name of the company is changing, our core values of integrity, quality, and continuous improvement remain steadfast. These steps are a celebration of our heritage and a move toward the future, building tomorrow together.

I've never been more excited about the company, and thank you for your support. Operator, we would now like to open the lines for questions.

Thank you. Just starting with, um—hello?

Good morning.

Morning. Jana, starting with automotive, I believe it's primarily Nexteer driving your steer-by-wire growth.

They remain your largest customer, as a 19% customer in the September quarter. What percent was Nexteer in December?

20.

20%? And—

Yes.

Thank you. Then, are your other customers also expanding that, or is it more braking that's driving some of the recovery there?

We are seeing steering and braking with our largest automotive customers, and that would be Nexteer, ZF, and HL Mando. It's not exclusive to Nexteer, but obviously globally Nexteer is our largest customer.

Okay. Yeah.

It's great to see that flattening out. Then on the growth side, can you remind us what the capacity is and ramp expectations are for this new facility in Indianapolis?

Yeah. The new facility in Indianapolis is 300,000 square feet under roof.

Considerably larger than our current footprint. It depends on the makeup of the volume of work that we've got to be able to tell you exactly what that's going to equate to in terms of revenue dollars, but significant opportunity for growth there.

We needed to demonstrate that for the types of business that we are courting for that facility.

Then, I think Philips remains your largest medical customer to date, but I imagine much of the work that you're doing in Indianapolis would be with some of your emerging, growing medical customers, or do I have that wrong?

No, you have that correct. As an example, if you look at the growth in Q2 and the year-to-date growth, it was split fairly evenly amongst North America, Europe, and Asia, and fairly evenly in the sub-verticals within medical, meaning it was not driven by respiratory care.

Medical for Kimball is growing. You're right, that CMO space would likely not have Philips content just because that's not the makeup of the business that we perform for them.

It would be new customers and expanded opportunities there.

Okay. Thank you.

Just final question. Is it more plastic injection molding or what are some of the value-added CMO applications that are drive your fastest-growing parts of the business?

Mike, it's Rick. Good morning.

Great question. We expect that facility, and again as Jana said, well, we'll be working with customers.

We're excited about our funnel and some of the discussions that we're having. We could imagine thinking of single-use surgical instruments, drug delivery devices such as auto-injectors, certainly, as you said, plastic injection molding we expect to be very significant.

We'll have significant capacity there. All of those are expected to be housed, at least partially, in that CMO facility in Indy.

Great. Thank you very much.

Thank you.

Thanks, Mike.

Hey. Thanks for taking the questions.

Hey, Jana. I wanted to start with automotive.

A little bit of softness in China and North America. Just given that you guys won't be comping against quarters in the past with the braking program in North America, just going forward, how should we think about sort of growth in the automotive piece for Q3 and Q4, sort of flattish declines year on year, sort of down single-digit percentages?

What's sort of the right way to think about automotive for the rest of the year?

Yeah. Great question.

We will finally anniversary the end of the EB100 program in Q3, and so what we would expect is Q3 automotive to be flat to potentially up just a little bit, because we've finally worked that through the system. We've got the two new programs in Europe, and Europe has been rebounding nicely for us.

In terms of automotive and the sluggishness, the worst of it is past us in Q1 and Q2.

Got it. That's helpful.

Then, Rick, just if you could comment on some of the win rates you're seeing across the business. Any sort of change in the size of the wins?

What sort of gets you excited for what you're seeing in the portfolio as you kind of look forward here? Thanks.

We're really excited, Derek, looking forward, and appreciate the question. We're seeing pretty consistent win rates.

Not that it's not very competitive out there, and there are certainly situations where we have program bidding situations where we decide we're not willing to accept a level of margin that's not for us. I wouldn't characterize it as anything but very competitive.

However, we feel the strengths that we have in those long-term customer relationships, our capabilities, our flexibility and quality and operations record, all of those things that we've talked about in the past continue to serve us very well. In terms of programs going forward, particularly in medical, but also in industrial, there's maybe a couple things that are worth note.

One is that we've always been open to and seeking what we call lift and shift opportunities. Where we're working with a customer who's currently doing their own manufacturing and has a desire to exit that for whatever reason to focus on R&D or marketing or sales or whatever is appropriate for them and have us take that over in our existing facility network.

We're seeing that activity in terms of those conversations increase, and those tend to be large programs, because it would be an example of a customer potentially shutting down an entire plant and moving that all into our footprint. Those are larger to the extent that we close those and we're excited about those discussions.

Then the CMO discussions that we're having also, those programs tend to be significantly larger than our typical average medical program just because the nature of that business, the growth in that business, and the scope and scale of what those customers are doing. Great question.

Got it. That sounds great.

Thanks.

Hi, and thank you for taking my questions. I'm just curious first, with this new facility that you're opening, as you ramp that, how should we think about that having an impact on the margin?

We certainly think over time that the CMO space has an opportunity for margins accretive to what you've seen from us historically. That's going to depend program by program and customer by customer, and again, all competitive situations.

We think that that space and our capabilities lends itself for that to be accretive in the long term.

Anja, I will tell you, in the near term, it's going to drag, right? Because we have all the depreciation expense, all of the additional expense associated with the opening of that facility.

We're currently running both facilities, right? Because we've got to move everything over, and then we'll have to close the facility.

For the next 6 to 9 months, or 2 to 3 quarters, it's going to be a drag. The reason that I want to point that out is the operating income margin that we produced in Q2, considering the fact that we had $16 million less sales and the impact of the grand opening of the Indy facility and other investments that we made, I think is a testament to our commitment as a leadership team to deliver value to the organization and into our shareholders.

It was a lot of work, and while we feel very confident in the strategy for the future, we're working hard to offset that drag in other areas of the business.

Thank you. Then how do you see the cash cycle days play out in the coming quarters?

That was quite elevated for the quarter.

Yeah. For the last 2 years, we've really been after cash conversion, cash cycling.

We've got a pretty aggressive PDSOH goal. We saw it tick up from 85 days to 90 days, primarily driven by North America and the impact of autos and industrials.

We saw inventory tick up a little bit. That remains a key focus of the organization.

We worked really, really hard to get working capital solid and inventory reductions and corresponding impact and debt on the balance sheet. You can expect that to continue to be a laser focus of us as a leadership team.

Said more plainly, I would expect Q3 to come back down from where it was in Q2.

Thank you. That was all for me.

I would like to, and I know no one asked, but I think it would just be helpful, give a little bit more color specifically on the remainder of the year. If you take the midpoint of our revenue guide at 1430, and you strip out the full year, or what we've done so far at 707, that leaves you with $723 million roughly to go.

What that would insinuate is that Q3 and 4 are going to be roughly in line with Q1 in terms of revenue growth. We already talked about autos and the fact that we've anniversaried EB100.

From a medical perspective, I would like to remind everyone that we had the consigned inventory sale in Q3 of FY '25 of $24 million. When we report Q3, we're going to give you the results, we will tell you what growth was in medical including the inventory sales and excluding the inventory sales.

We won't make you do that math, but I just wanted to remind everybody of that. Then it's industrial North America, and that's where our focus is going to continue to be in terms of seeing how that's going to shake out.

Just as everybody's fine-tuning their models, some additional color I thought might be helpful for you.

Hey, guys. Thanks for taking my question.

Thanks for the color on the model, too. If we look at automotive, I was just hoping if you could provide some more color on maybe the opportunity with the EPP, the electronic power pack program, and then kind of some of the opportunities around the OEMs with the second steering design.

Can these become similar in size to the old braking program that ended up going away, or kind of just help me out with where the potential is with these two programs?

We were really excited about the EPP program because it's our first higher-level assembly in automotive, where you're combining the motor and the printed circuit board assembly. That's really exciting.

In terms of size of the program, the EPP is not as big as the braking program was. It's probably about two-thirds of that size.

From a future strategic focus in automotive, it's really excited. The other thing that I'll say is as you think about the continuum of opportunity in automotive, particularly as it relates to ADAS, right, you've got steering programs now, you've got braking programs now, steer-by-wire, brake-by-wire, that's all really exciting.

You also have ADAS, where it's, hey, there's going to be a central brain functioning in the car that's going to be controlling all of the electronics in there. That's something that Kimball is also interested in pursuing in the future.

We would expect as EPP becomes more common in vehicles, as second steering column becomes more common in vehicles, and ADAS, that those are strategic areas that we would want to participate in. Right?

I remember when autonomous driving, lane departure features were only available in very, very high-end cars. Now they're everywhere, right?

A Nissan Sentra's got it. Everybody everywhere is offering that feature.

It's exciting in terms of the strategic opportunities for automotive.

Awesome. Thank you.

Next one. If we look at the medical space, you talked about inorganic opportunities last quarter, I don't think you had in the prepared remarks in this call, but we look at some of the things you guys provide with the auto-injectors, sleep therapy, drug delivery, when you're looking at acquisitions, what are some of the other spaces, or let's call them sub-verticals, that you guys are looking at where you're seeing some great opportunities?

Hey, Max, it's Andy. We have done a fairly deep dive on end-market exposures, and in vitro diagnostics is really interesting to us, cardiology is really interesting to us.

We would certainly consider opportunities or adjacencies to expand into those areas, especially if it provided a chance to either expand a relationship with an existing customer or add a new customer, and the same for manufacturing capabilities.

All righty, I'll take the rest of mine offline. Thanks, guys.

Thank you.